RXRX
Recursion Pharmaceuticals Inc
3.80$
+8.2%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | +194.4% | +104.4% | +14.9% | -6.8% | +121.6% | +1.8% | |
| – | +248.7% | +100.7% | +6.6% | -23.1% | +63.0% | +13.8% | |
| – | +275.1% | +8.8% | +92.9% | -28.8% | +51.8% | +25.1% | |
| – | +275.1% | +97.1% | +6.5% | -28.8% | +51.8% | +25.1% | |
| – | +3.3% | +5,726.9% | -69.7% | +12.4% | +1,489.1% | -49.9% | |
| – | -4.7% | -69.2% | -17.5% | -341.7% | – | – | |
| – | +6.6% | +149.3% | +87.6% | – | – | – | |
| – | – | +0.0% | +0.0% | +6,398.9% | +186.0% | +8.9% | |
| – | – | -18.0% | -5.7% | +2,690.4% | +821.6% | -7.7% | |
| – | +123.7% | -86.6% | +219.7% | -11.7% | +117.5% | -17.0% | |
| – | +245.6% | +102.0% | +114.9% | -7.1% | +101.2% | -21.2% | |
| – | +183.1% | -2.2% | +301.7% | +1.8% | +260.9% | -2.1% | |
| – | -14.8% | +162.5% | +62.7% | -13.8% | +446.7% | -16.2% | |
| – | -8.1% | -94.5% | -15.3% | +105.4% | +1,627.7% | -49.7% | |
| – | – | – | -10.5% | -4.6% | +123.3% | +9.3% | |
| – | – | – | – | – | – | – | |
| – | +0.0% | +2.7% | +3.1% | +18.4% | +31.9% | +63.2% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.